Dakin Leslie A, Xing Li, Hall Justin, Ding Weidong, Vajdos Felix F, Pelker Jeffrey W, Ramsey Simeon, Balbo Paul, Sahasrabudhe Parag V, Banker Mary Ellen, Choi Won Young, Wright Stephen W, Chang Jeanne S, Curto John M, Davoren Jennifer E, Drozda Susan E, Fennell Kimberly F, Futatsugi Kentaro, Kortum Steve, Lee Katherine L, Liu Shenping, Lovering Frank, Nicki Jennifer A, Trujillo John I, Vincent Fabien, Schnute Mark E
Medicine Design, Pfizer Inc, Cambridge, MA, USA.
Medicine Design, Pfizer Inc, Groton, CT, USA.
Nat Commun. 2025 May 16;16(1):4579. doi: 10.1038/s41467-025-59919-4.
Peptidylarginine deiminases (PAD1-4) are calcium dependent enzymes responsible for protein citrullination, a post-translational modification converting arginine residues to citrulline. Elevated levels of citrullinated proteins have been associated with rheumatoid arthritis, neurodegenerative diseases, and cancers. Though highly selective PAD4 inhibitors have been described, inhibitors to the broader family currently are limited to covalent substrate analogs. Herein, we describe an allosteric binding pocket common to PAD1-4 suitable for the identification of potent, non-covalent enzyme inhibitors. A ligand-based virtual screen is utilized to identify a PAD4 inhibitor for which surface plasmon resonance confirms target binding but non-competitively with a known PAD4 ligand. We further show through co-crystal structure analysis that the ligand binds PAD4 at an allosteric pocket resulting in stabilization of a catalytically inactive, calcium-deficient enzyme conformation. A ligand designed based on this site potently inhibits all four PAD isozymes and prevents protein citrullination in neutrophils with a broader protein repertoire than observed with a PAD4-selective inhibitor.
肽基精氨酸脱亚氨酶(PAD1 - 4)是钙依赖性酶,负责蛋白质瓜氨酸化,这是一种将精氨酸残基转化为瓜氨酸的翻译后修饰。瓜氨酸化蛋白水平升高与类风湿性关节炎、神经退行性疾病和癌症有关。尽管已经报道了高度选择性的PAD4抑制剂,但目前针对更广泛家族的抑制剂仅限于共价底物类似物。在此,我们描述了一个PAD1 - 4共有的变构结合口袋,适用于鉴定有效的非共价酶抑制剂。基于配体的虚拟筛选用于鉴定一种PAD4抑制剂,表面等离子体共振证实其与靶点结合,但与已知的PAD4配体无竞争性。我们通过共晶体结构分析进一步表明,该配体在变构口袋处结合PAD4,导致催化无活性、钙缺乏的酶构象稳定。基于该位点设计的配体可有效抑制所有四种PAD同工酶,并防止中性粒细胞中的蛋白质瓜氨酸化,其作用的蛋白质种类比PAD4选择性抑制剂更广泛。